NR1I2 and cancer: The higher expression of PXR in breast [7], esophageal [11], endometrial [10], prostate [8] and colon [3] cancers has been shown to be associated with higher expression of drug metabolizing enzymes and drug transporters, which leads to multidrug resistance and favours progression of cancer.